Risk stratification and medical therapy of pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Respir J
Main Authors: Galiè, Nazzareno, Channick, Richard N., Frantz, Robert P., Grünig, Ekkehard, Jing, Zhi Cheng, Moiseeva, Olga, Preston, Ioana R., Pulido, Tomas, Safdar, Zeenat, Tamura, Yuichi, McLaughlin, Vallerie V.
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2019
Assuntos:
Series
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6351343/
https://ncbi.nlm.nih.gov/pubmed/30545971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.01889-2018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados